PBYI Stock Analysis: Buy, Sell, or Hold?
PBYI - PUMA BIOTECHNOLOGY INC
$8.04
0.38 (4.96%)
▲
5d:
+13.72%
30d:
+14.04%
90d:
+28.64%
HOLD
MODERATE Confidence
Analysis Updated: Jun 23, 2026 12:00 AM ET
Earnings: Aug 06, 2026
Get Alerted When PBYI Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD - EXTENDED: PBYI is 8.4% above its trading range ($7.42). Fundamentals are solid but entry is stretched. Hold existing positions; wait for pullback to add new shares.
📊 HOLD - EXTENDED: PBYI is 8.4% above its trading range ($7.42). Fundamentals are solid but entry is stretched. Hold existing positions; wait for pullback to add new shares.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$2.73
Based on -9.1% avg growth
INTRINSIC VALUE TODAY
$1.69
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 12.9x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: PBYI is currently trading at $8.04, which is considered extended relative to its 30-day fair value range of $6.87 to $7.42. From a valuation perspective, the stock is trading at a premium (Forward PE: 23.0) compared to its historical average (12.9). At these levels, the market is pricing in 21.3% annual earnings growth.
Technical Outlook: Technically, PBYI is in a uptrend. The price is approaching resistance at $7.45. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 5.0% recently.
Market Sentiment: PBYI has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. However, the stock is trading significantly above the average Wall Street target of $5.00. The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, PBYI is in a uptrend. The price is approaching resistance at $7.45. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 5.0% recently.
Market Sentiment: PBYI has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. However, the stock is trading significantly above the average Wall Street target of $5.00. The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$6.87 -
$7.42
Company Quality Score
60/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
64.2%
All Signals
- BEARISH: Price extended above range (+8.4% above its trading range)
- BULLISH: Options cheap (IV 0th percentile)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+5.0%)
- BEARISH: Trading 37.8% above Wall St target ($5.00)
- BULLISH: Expecting earnings turnaround to 21.3% growth with -2.6% revenue growth
- CAUTION: Extended 8.4% above its trading range - wait for pullback
Trading Range Analysis
30-Day Trading Range
$6.87 -
$7.42
Current vs Trading Range
EXTENDED
Expected Move (7 Days)
±$0.88
(11.0%)
Support & Resistance Levels
Support Level
$6.78
Resistance Level
$7.45
Current Trend
Uptrend
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
22.97
Wall Street Target
$5.00
(-37.8%)
Revenue Growth (YoY)
-2.6%
Earnings Growth (YoY)
-34.4%
Profit Margin
10.7%
Valuation Premium vs History
+21.3% premium
PE vs Historical
23.0 vs 12.9
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+21.3%
(market-implied from PE analysis)
1-Year Target
$9.75
(+21%)
2-Year Target
$11.83
(+47%)
3-Year Target
$14.35
(+79%)
3-Yr Target (if PE normalizes)
(PE: 23→13)
PE COMPRESSION
$8.06
(+0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 23.0, Growth: -22.2%)
$5.86
(+-27%)
Base:
(SPY PE: 21.8, Growth: -22.2%)
$5.56
(-31%)
Bear:
(PE: 12.9, Growth: -22.2%)
$3.29
(-59%)
📈
Valuation based on Current Earnings
Trailing PE: 15.96 | Current EPS (TTM): $0.48
Bull Case
$6.14
(-24%)
Analyst growth -27.1%, PE expands to 17.6
Base Case
$5.59
(-31%)
Market implied -27.1%, PE stable at 16.0
Bear Case
$5.21
(-35%)
Severe decline -20.0%, PE contracts to 13.6
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: June 23, 2026 8:54 PM ET
Data refreshes hourly during market hours. Next update: 9:54 PM
Data refreshes hourly during market hours. Next update: 9:54 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PBYI showing a specific setup today?
Insider Activity (6 Months)
0
Buys
4
Sells
Net
INSIDERS SELLING
Recent Transactions
Alan H Auerbach
SELL
18012 shares
2026-01-07
Douglas M Hunt
SELL
5014 shares
2026-01-07
Alan H Auerbach
SELL
16938 shares
2026-01-06
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$833 | 67 BUY |
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$105 | 64 BUY |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$34 | 61 BUY |
|
MLTX
MoonLake Immunotherapeut… |
STRONG BUY
16 analysts |
$28 | 65 BUY |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$102 | 65 BUY |
